Predictive prognostic value of N L ratio in acute coronary syndrome
Written By : Dr. Nandita Mohan
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2022-09-07 04:15 GMT | Update On 2022-09-08 06:11 GMT
A study in Indian Heart Journal assessed the relationship between neutrophil-lymphocytes ratio (NLR) at admission and patient outcome over a period of six month in subjects with acute coronary syndrome (ACS).A total of 435 consecutive patients presenting with acute coronary syndrome were enrolled and 400 patients completed the study. Patients were categorized into 2 groups: the NLR group 1...
Login or Register to read the full article
A study in Indian Heart Journal assessed the relationship between neutrophil-lymphocytes ratio (NLR) at admission and patient outcome over a period of six month in subjects with acute coronary syndrome (ACS).
A total of 435 consecutive patients presenting with acute coronary syndrome were enrolled and 400 patients completed the study. Patients were categorized into 2 groups: the NLR group 1 and the NLR group 2.
Study found that Forty-seven (11.8%) patients died during 6 months follow up. Higher mortality was seen in NLR group 2 compared to NLR group 1.
Study concludes that elevated neutrophil-lymphocyte ratio is independently associated with higher all-cause mortality rate up to 6 months period irrespective of acute coronary syndrome type.
Reference: Bajari R, Tak S. Predictive prognostic value of neutrophil-lymphocytes ratio in acute coronary syndrome. Indian Heart J. 2017 Apr;69 Suppl 1(Suppl 1):S46-S50. doi: 10.1016/j.ihj.2017.01.020. Epub2017 Feb 7. PMID: 28400038; PMCID: PMC5388019.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd